GB Patent

GB2478074A — THC and CBD for use in the treatment of tumours

Assigned to GW Pharma Ltd · Expires 2011-08-24 · 15y expired

What this patent protects

A combination of cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD). for use in the treatment of a tumour, to reduce cell viability, inhibit cell growth or reduce tumour volume. Preferably the tumour is a brain tumour, more specifically a glioma or glioblastoma. Prefer…

USPTO Abstract

A combination of cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD). for use in the treatment of a tumour, to reduce cell viability, inhibit cell growth or reduce tumour volume. Preferably the tumour is a brain tumour, more specifically a glioma or glioblastoma. Preferably the compounds are in the ratio of 5:1 to 1:5. The cannabinoids may be present as plant extracts and may be administered separately, sequentially or simultaneously.

Drugs covered by this patent

Patent Metadata

Patent number
GB2478074A
Jurisdiction
GB
Classification
—
Expires
2011-08-24
Drug substance claim
No
Drug product claim
No
Assignee
GW Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.